Medicare is about to let some people get GLP-1 weight-loss drugs for $50 a month. That sounds simple. This is American healthcare, so naturally, there is a bridge, a toll booth, several eligibility signs, and a pharmacist trying to find the right billing code. For the past few years, the GLP-1 weight-loss drugs story has mostly sounded like this: A patient hears about Wegovy or Zepbound. A doctor agrees it may help. The patient walks to the pharmacy. The pharmacy says somethi

The complexities of expired Ozempic patent and medical tourism

As AI races ahead, America’s obesity crisis is still grounded in costly reality. This March 2026 PoundsPunch feature examines how GLP-1 drugs, new policy experiments, supply-chain strain, and global generic competition are reshaping the future of weight loss treatment.

Why does the weight come back so fast after stopping GLP-1 drugs?

Wegovy can cost over $1,300 a month—but 340B quietly reshapes who pockets that money. We follow the dollars from patient to hospital, pharmacy, PBM, and Novo Nordisk.

Lilly’s once‑daily pill posts late‑stage successes. Here’s what the data really say, how it stacks up against rivals, and what to expect on price, coverage, and patient experience.

The new drugs, the China and India's ambition, and Bernie Sanders' pricing probe.